Interestingly the well-tolerance and the absence of effects on MKK3 signalling of either AT9283 or alisertib when tested in primary colonocytes (CCD-18Co) suggested the relevance of MKK3/AURKA crosstalk only in cancer cell context, prompting to suggest a novel vulnerability to be targeted for the development of novel therapeutic strategies to manage late-stage and metastatic CRC patients. The gene discussed is MAP2K3; the disease is cancer.